
Payer HEOR Submission Analysis & Coverage Recommendation Framework
Analyze manufacturer HEOR submissions and generate evidence-based payer coverage recommendations
What You Can Do
You can rapidly extract and validate key claims from manufacturer HEOR dossiers (typically 200+ pages), assess cost-effectiveness calculations against payer willingness-to-pay thresholds, identify evidence gaps and potential bias, and generate formulary recommendations with documented rationale for P&T committee review. This framework reduces typical 3-5 hour manual analysis to 90 minutes of focused, traceable review.
Features
automatically identifies clinical efficacy claims, economic model assumptions, and comparative evidence from unstructured submissions
tests manufacturer calculations against standard payer thresholds and flags methodological concerns
surfaces missing comparators, underrepresented populations, and insufficient real-world data
flags selective outcome reporting, unfavorable comparator choice, and model parameter manipulation
translates findings into formulary tier placement, prior authorization criteria, or coverage policy language
generates decision memos with evidence grading and rationale for committee review
handles new drug approvals, indication expansions, biosimilar launches, and contract renewal scenarios
Example Output
Example 1: Cost-Effectiveness Review
- ICER Claim: $62,000/QALY vs. standard therapy
- Framework Output: Methodology sound. Model uses 10-year time horizon appropriate for chronic disease. Sensitivity analysis adequate. Within payer threshold ($75K). Recommend preferred tier. Risk: Manufacturer assumes 85% adherence; real-world data shows 62%. Recommend outcomes-based contract clause.
Example 2: Evidence Gap Identification
- Submission compares only to Drug A (poorly effective, off-patent)
- Missing: Comparison to Drug B (current preferred agent, same mechanism, similar cost)
- Missing: Subgroup efficacy data for patients with renal impairment (25% of target population)
- Framework Output: Insufficient evidence for broad coverage. Recommend limiting to treatment-naive patients pending comparative effectiveness vs. Drug B.
Example 3: Coverage Recommendation
- Drug: New GLP-1 agonist for Type 2 diabetes
- Framework Output: Recommended Coverage Policy: Tier 2 preferred. PA required if: patient BMI <30, HbA1c >10%, or prior GLP-1 failure documented. Annual cost limit triggers rebate review.
What's Included
- SKILL.md instruction file with framework overview and decision triggers:
- HEOR submission template checklist: identifies 40+ data points to extract from manufacturer dossiers
- Cost-effectiveness validation worksheet: step-by-step model review against payer standards
- Evidence gap assessment framework: systematic comparison methodology checklist
- Coverage recommendation memo template: P&T-ready documentation with evidence grading and rationale fields
- Bias assessment rubric: 12-point methodology audit for common HEOR pitfalls
Who It's For
- Payer HEOR analysts — evaluating manufacturer submissions for coverage decisions
- P&T committee members — reviewing clinical and economic evidence for formulary placement
- Medical directors — validating health economic claims and determining coverage policy
- Pharmacy benefit managers — assessing cost-effectiveness of new drugs and indications
- Market access managers at manufacturers — preparing HEOR dossiers aligned with payer expectations
Best For
- New drug FDA approval HEOR submission evaluation
- Indication expansion and line extension coverage review
- Biosimilar comparative effectiveness dossier analysis
- Annual formulary contract negotiation and rebate justification
- HTA submission counter-evidence preparation for international markets
- Cost-effectiveness threshold validation and willingness-to-pay assessment
- Prior authorization criteria development based on clinical evidence







